ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

From Startup ARQULE

Link to Full Article:

BURLINGTON, Mass.–(BUSINESS WIRE)–Nov. 14, 2018–
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Marc Schegerin, Senior Vice President, Head of
Strategy, Finance, and Communication will present at the 30th Annual
Piper Jaffray Healthcare Conference on November 28, 2018, at 1:50pm ET
at the Lotte New York Palace in New York City.

The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website,,
under “Events & Presentations.” A replay of the webcast will be
available shortly after the conclusion of the presentation.

About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet need
that will dramatically extend and improve the lives of our patients. Our
clinical-stage pipeline consists of five drug candidates, all of which
are in targeted, biomarker-defined patient populations, making ArQule a
leader among companies our size in precision medicine. ArQule’s pipeline
includes: ARQ 531, an orally bioavailable, potent and reversible
inhibitor of both wild type and C481S-mutant BTK, in Phase 1 for
patients with B-cell malignancies refractory to other therapeutic
options; Miransertib (ARQ 092), a selective inhibitor of the AKT
serine/threonine kinase, in a Phase 1/2 company-sponsored study for
Overgrowth Diseases, in a Phase 1 study for ultra-rare Proteus syndrome
conducted by the National Institutes of Health (NIH), and in Phase 1b in
combination with the hormonal therapy, anastrozole, in patients with
advanced endometrial cancer; ARQ 751, a next generation AKT inhibitor,
in Phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the fibroblast
growth factor receptor (FGFR) family, in a registrational trial for
iCCA; and ARQ 761, a β-lapachone analog being evaluated as a promoter of
NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple
oncology indications in partnership with the University of Texas
Southwestern Medical Center. ArQule’s current discovery efforts are
focused on the identification and development of novel kinase
inhibitors, leveraging the Company’s proprietary library of compounds.

View source version on
Source: ArQule, Inc.
Corporate Contact:Marc Schegerin, M.D.Senior Vice
PresidentHead of Strategy, Finance and Communicationir@arqule.comMedia
Contact:Allison Blum, Ph.D.LifeSci Public Relations

Please visit their site for more information:
All,Biotechnology,Healthcare News
2018-11-15 05:11:03